silvercontaining solution silver sequence dna staining reagents (Promega)
90
Structured Review
Promega
silvercontaining solution silver sequence dna staining reagents
Silvercontaining Solution Silver Sequence Dna Staining Reagents, supplied by Promega, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/silvercontaining+solution+silver+sequence+dna+staining+reagents/silvercontaining+solution+silver+sequence+dna+staining+reagents/pm15112277-100-7-14
Average 90 stars, based on 1 article reviews
Silvercontaining Solution Silver Sequence Dna Staining Reagents, supplied by Promega, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/silvercontaining+solution+silver+sequence+dna+staining+reagents/silvercontaining+solution+silver+sequence+dna+staining+reagents/pm15112277-100-7-14
Average 90 stars, based on 1 article reviews
silvercontaining solution silver sequence dna staining reagents - by Bioz Stars,
2026-10
90/100 stars
Images
Related Articles
Staining:Article Title: P53 and K-ras mutations are frequent events in microscopically negative surgical margins from patients with nonsmall cell lung carcinoma. Article Snippet: Received September 3, 2003; revision received December 22, 2003; accepted February 3, 2004.. BACKGROUND.. The objective of the current study was to determine whether tumor cells harboring P53 and K-ras mutations could be detected in histopathologically tumor-free surgical margins in patients with nonsmall cell lung carcinoma who underwent complete pulmonary resection. Sequencing:Article Title: P53 and K-ras mutations are frequent events in microscopically negative surgical margins from patients with nonsmall cell lung carcinoma. Article Snippet: Received September 3, 2003; revision received December 22, 2003; accepted February 3, 2004.. BACKGROUND.. The objective of the current study was to determine whether tumor cells harboring P53 and K-ras mutations could be detected in histopathologically tumor-free surgical margins in patients with nonsmall cell lung carcinoma who underwent complete pulmonary resection. |